These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 32727211)
1. Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis. Zhu X; Cao G Clin Appl Thromb Hemost; 2020; 26():1076029620942594. PubMed ID: 32727211 [TBL] [Abstract][Full Text] [Related]
7. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. De Luca G; Navarese E; Marino P Eur Heart J; 2009 Nov; 30(22):2705-13. PubMed ID: 19875386 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572 [TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Truong KM; Amankwa K; Kucukarslan S Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855 [TBL] [Abstract][Full Text] [Related]
10. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Mandava P; Thiagarajan P; Kent TA Drugs; 2008; 68(8):1019-28. PubMed ID: 18484795 [TBL] [Abstract][Full Text] [Related]
14. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Memon MA; Blankenship JC; Wood GC; Frey CM; Menapace FJ Am J Med; 2000 Aug; 109(3):213-7. PubMed ID: 10974184 [TBL] [Abstract][Full Text] [Related]
15. An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives. Sharifi-Rad J; Sharopov F; Ezzat SM; Zam W; Ademiluyi AO; Oyeniran OH; Adetunji CO; Roli OI; Živković J; Martorell M; Docea AO; El Omari N; Bouyahya A; Lorenzo JM; Calina D High Blood Press Cardiovasc Prev; 2023 Mar; 30(2):93-107. PubMed ID: 36637623 [TBL] [Abstract][Full Text] [Related]
16. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258 [TBL] [Abstract][Full Text] [Related]
17. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. Iskandar SB; Kasasbeh ES; Mechleb BK; Garcia I; Jackson A; Fahrig S; Albalbissi K; Henry PD J Interv Cardiol; 2006 Aug; 19(4):356-63. PubMed ID: 16881986 [TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms. Dornbos D; Katz JS; Youssef P; Powers CJ; Nimjee SM Neurosurgery; 2018 Mar; 82(3):268-277. PubMed ID: 28472526 [TBL] [Abstract][Full Text] [Related]